Pallas Capital Advisors’s 10x Genomics TXG Stock Holding History

Pallas Capital Advisors’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.86M	Sell	48,640 -277	-0.6%	-$7.26K	0.06%	226
2026 Q1	$1.04M	Sell	48,917 -2,780	-5%	-$55.6K	0.04%	321
2025 Q4	$843K	Sell	51,697 -2,903	-5%	-$43.9K	0.03%	395
2025 Q3	$638K	Sell	54,600 -2,176	-4%	-$28.4K	0.02%	450
2025 Q2	$657K	Buy	56,776 +32,996	+139%	+$301K	0.03%	424
2025 Q1	$208K	Buy	+23,780	New	+$300K	0.01%	683

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Pallas Capital Advisors's TXG Position: Q2 2026 in Review

Pallas Capital Advisors reduced its 10x Genomics (TXG) stake by 0.57% in Q2 2026, selling an estimated $7.26K and leaving 48,640 shares worth $1.86M. The position accounts for 0.06% of the portfolio, ranked #226.

Pallas Capital Advisors first reported a position in TXG in Q1 2025 and has held it in 6 quarters since. 393 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

Pallas Capital Advisors held 48,640 shares of 10x Genomics worth $1.86M as of Q2 2026.
Pallas Capital Advisors sold 277 10x Genomics shares in Q2 2026, an estimated $7.26K.
10x Genomics made up 0.06% of Pallas Capital Advisors's portfolio in Q2 2026, its #226 holding.
Pallas Capital Advisors first reported a position in 10x Genomics in Q1 2025 and has held it in 6 quarters since.
393 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Pallas Capital Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.